Use of phosphordiesterase inhibitors in the treatment of prostatic diseases

Medicaments for the prophylaxis and treatment of prostatic diseases, in particular benign prostatic hyperplasia, the so-called urge symptoms, pollacuria (frequent micturition), nycturia (nocturnal micturition), weakened urine jet, urge incontinence (involuntary discharge of urine), prostatism, instabilities of the bladder muscles, and impotence, containing a component selected from the group of

• a) 2-(2-propoxyphenyl-)8-azapurin-6-one (zaprinast);
• 19
• b) dipyridamole;
• 20
• c) 1-(3-chlorophenylamino)-4-phenylphthalazine (MY5445);
• 21
• d) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355);
• 22
• e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);
• f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxy-quinazoline;
• 23
• g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (Sildenafil);
• 24
• h) (2-n-butyl-5-chloro-1-(2-chlorobenzyl)4-methylacetate-imidazole;
• 25
• i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237);
• 26
• j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxy-propoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-55712);
• 27
• k) quinazolines and their trimethoxy derivatives;
• l) pyrazolopyrimidones;
• as well as pharmacologically compatible salts thereof.

Use of a component in the preparation of medicaments for the prophylaxis and treatment of prostatic diseases, in particular benign prostatic hyperplasia, the so-called urge symptoms, pollacuria (frequent micturition), nycturia (nocturnal micturition), weakened urine jet, urge incontinence (involuntary discharge of urine), prostatism, instabilities of the bladder muscles, and impotence, selected for the group of

• a) 2-(2-propoxyphenyl-)8-azapurin-6-one (zaprinast);
• 28
• b) dipyridamole;
• 29
• c) 1-(3-chlorophenylamino)-4-phenylphthalazine (MY5445);
• 30
• d) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355);
• 31
• e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);
• f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxy-quinazoline;
• 32
• g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (Sildenafil);
• 33
• h) (2-n-butyl-5-chloro-1-(2-chlorobenzyl)4-methylacetate-imidazole;
• 34
• i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237);
• 35
• j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxy-propoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-55712);
• 36
• k) quinazolines and their trimethoxy derivatives;
• l) pyrazolopyrimidones;
• as well as pharmacologically compatible salts thereof.